My Optics ETF - Updated!

Gaetano · Gaetano · 31 августа 2026, 02:13 · ⏱ 1 мин чтения  | Читать в Substack ↗
Резюме
Gaetano is repositioning his Photonics Mock ETF around a 2+ year investment horizon, cutting higher-risk/pre-inflection names and restricting the portfolio to U.S.-listed, more established optics companies. This implies a deliberate shift away from speculative European photonics exposure until those businesses show more commercial proof, favoring durable U.S.-listed optics/photonics names for broad multi-year allocation.
  • The mock ETF will be updated every couple of months and is built with a 2+ year investment mindset, not as a short-term trade list.
  • The number of positions has been reduced and higher-risk companies removed; pre-inflection companies may be added later as they gain commercial proof.
  • The updated version is U.S.-listed only; the prior European exposure was dropped because Gaetano does not think many of those names offer a good multi-year outlook.
  • Gaetano says he likes IQE, SIVE and SMOP, but believes for the most part they still have a lot to prove.
Время чтения 1 мин
Объём 1,299 симв.
Категория finance
Идеи
crux_capital_ Independent Photonics & AI Infrastructure Researcher
Gaetano explicitly says 'I like IQE... but for the most part they still have a lot to prove' and says he would add pre-inflection companies as they get commercial proof, making IQE a conditional long
Gaetano explicitly says 'I like IQE... but for the most part they still have a lot to prove' and says he would add pre-inflection companies as they get commercial proof, making IQE a conditional long candidate. Risk: Ongoing lack of commercial proof could keep it excluded from the long-term portfolio and delay any buyer interest.
crux_capital_ Independent Photonics & AI Infrastructure Researcher
Gaetano names SIVE among European photonics names he likes, but excludes it from the U.S.-listed long-term ETF because it still has a lot to prove; commercial milestones are the trigger to add.
Gaetano names SIVE among European photonics names he likes, but excludes it from the U.S.-listed long-term ETF because it still has a lot to prove; commercial milestones are the trigger to add. Risk: As a smaller/pre-inflection photonics name, execution risk and commercialization timing remain the main downside.
crux_capital_ Independent Photonics & AI Infrastructure Researcher
Gaetano includes SMOP with IQE and SIVE as names he likes, but indicates they still have a lot to prove, so the stock stays on a conditional watch until commercial traction is demonstrated.
Gaetano includes SMOP with IQE and SIVE as names he likes, but indicates they still have a lot to prove, so the stock stays on a conditional watch until commercial traction is demonstrated. Risk: Failure to deliver commercial proof means it remains outside the stable long-term portfolio and faces potential further derating.
Ещё от Gaetano

This newsletter, published August 31, 2026, features crux_capital_ discussing IQE, SIVE, SMOP. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: crux_capital_  · Tickers: IQE, SIVE, SMOP